Scarica l'app Stockscreener
49.32
4.18%
1.97
Precedente Chiudi:
$47.35
Aprire:
$47.99
Volume 24 ore:
47,821
Relative Volume:
0.35
Capitalizzazione di mercato:
$1.73B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+14.96%
1M Prestazione:
+32.75%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$47.73
$49.93
Intervallo di 1 settimana:
$42.58
$50.85
Portata 52W:
$32.00
$51.56
Veradermics Inc Stock (MANE) Company Profile
Compare MANE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
49.40 | 1.66B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.94 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.57 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
730.65 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.71 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.05 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Veradermics Inc Borsa (MANE) Ultime notizie
Veradermics to Participate in Upcoming March Investor Conferences - Business Wire
Veradermics, Incorporated: Revenue and Earnings Analysts Forecasts Revisions | MANE | US9229671048 - marketscreener.com
MANE Technical Analysis & ETF Price Forecast - Intellectia AI
Veradermics, Incorporated: Dividend historical data and projections - marketscreener.com
Leerink initiates Veradermics stock with Outperform rating By Investing.com - Investing.com UK
Cantor Fitzgerald Initiates VeraDermics at Overweight - marketscreener.com
Jefferies Initiates VeraDermics at Buy With $75 Price Target - marketscreener.com
Citigroup Initiates VeraDermics at Buy With $85 Price Target - marketscreener.com
Leerink Initiates VeraDermics at Outperform With $75 Price Target - marketscreener.com
Veradermics eyes FDA first as Jefferies initiates at 'buy'; sees 75% upside on oral hair loss pill - Proactive financial news
Leerink initiates Veradermics stock with Outperform rating - Investing.com Nigeria
Jefferies initiates Veradermics stock with buy rating on phase 3 prospects - Investing.com Canada
Cantor Fitzgerald initiates Veradermics stock with Overweight rating - Investing.com India
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell – Company Announcement - Financial Times
Longitude investors disclose 12.5% Veradermics (MANE) stake after IPO - Stock Titan
Assessing Veradermics (MANE) Valuation After Recent Share Price Move And Persistent Pre Revenue Losses - Yahoo Finance
Veradermics completes enrollment in second pivotal phase 3 clinical trial of Vdphl01 for male pattern hair loss - marketscreener.com
Veradermics Completes Enrollment in 2nd Phase 3 Study of VDPHL01 for Male Pattern Hair Loss - marketscreener.com
Veradermics completes enrollment in phase 3 trials for hair loss drug - Investing.com Canada
Completion of VDPHL01 Phase 3 Enrollment for Male Pattern Hair Loss - Intellectia AI
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss - Business Wire
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report - biocentury.com
Finance Watch: Four IPOs In One Week - Citeline News & Insights
A sign biotech is back? Four drugmakers go public, raising nearly $1 billion in all - statnews.com
Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering - BioSpace
Veradermics completes $294.8 million IPO with full underwriter option exercise - Investing.com
Veradermics CEO has a great hair day with 122% pop in IPO - Endpoints News
Hair regrowth biotech raises $256m in ‘upsized’ IPO - longevity.technology
Veradermics’ IPO raises $256M in stellar NYSE debut - Hartford Business Journal
Veradermics Raises $256 Million in Upsized Initial Public Offering - Pharmaceutical Executive
A cut above: Veradermics locks in $256M IPO and shares spike - Fierce Pharma
Veradermics announces pricing of upsized IPO - The Pharma Letter
Eikon, Veradermics close IPOs, as Salspera joins queue - pharmaphorum
Ropes Leads Hair-Loss Firm Veradermics' Upsized $256M IPO - Law360
Veradermics, Inc. (MANE): Dermatology Biotech Blasts Off, Eli Lilly and Wellington Anchor Hot IPO - Smartkarma
Baldness Biotech Veradermics Prices $256M IPO for Pivotal Tests of Pill for Hair Loss - MedCity News
Veradermics prices upsized IPO at $17 per share, raises $256.3 million - Investing.com Nigeria
Veradermics, Dermatology-Focused Biopharma Developing Extended-Release Oral Minoxidil for Pattern Hair Loss, Files for NYSE IPO - TradingView
MANE Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Hair Loss Firm Veradermics Jumps 124% After $256 Million IPO - Bloomberg
No Revenue? No Problem. Biotech Targeting Hair Loss Doubles in Stock IPO. - Barron's
Soaring Veradermics IPO Shows Investor Interest In Hair-Loss Companies Isn’t Thinning - Crunchbase News
Veradermics stock soars 118% in NYSE debut after upsized IPO By Investing.com - Investing.com South Africa
Veradermics stock soars 118% in NYSE debut after upsized IPO - Investing.com
Veradermics stock surges on public debut (MANE:NYSE) - Seeking Alpha
Veradermics soars in NYSE debut after upsized $256.3 million IPO - TradingView
Veradermics opens at $34, IPO priced at $17 per share - TipRanks
Veradermics Shares More Than Double in NYSE Debut - marketscreener.com
Veradermics indicated to open at $20-$22, IPO priced at $17 - TipRanks
Veradermics IPO: $256.3M Raised for Biotech's Hair Restoration Therapy | 2026News and Statistics - IndexBox
Veradermics prices upsized IPO at $17 per share, raises $256.3 million By Investing.com - Investing.com South Africa
Veradermics Inc Azioni (MANE) Dati Finanziari
Non sono disponibili dati finanziari per Veradermics Inc (MANE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):